Federal award
REGENERON PHARMACEUTICALS INC
W15QKN21C0014
Contract
Obligated and Ceiling
- Obligated (net)
- $5,565,000,000.00
- Ceiling (potential value, not spending)
- $5,565,000,000.00
- Current value
- $5,565,000,000.00
- Gross positive obligations
- $5,565,000,000.00
Obligated is what the government has committed, net of de-obligations. The ceiling is the most the award or vehicle could ever reach; it is shown separately and never added to, or compared as, spending.
Award Details
- Recipient
- REGENERON PHARMACEUTICALS INC · N3F9MH7E6HD6
- Owner company
- Not a reviewed companyNo reviewed company owns this recipient.
- Reported parent
- REGENERON PHARMACEUTICALS INC · N3F9MH7E6HD6
- Awarding agency
- Department of War · sub-agency 2100 · office W58P05
- Funding agency
- Department of War · sub-agency 2100
- Product or service (PSC)
- 6505 · DRUGS AND BIOLOGICALS
- Industry (NAICS)
- 325414 · BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING
- PIID
- W15QKN21C0014
- Award type code
- D
- Actions
- 8 · Jan 12, 2021 to Jul 29, 2022
- Why it is listed
- gross positive obligations of $100k or more (contracts)
Action History8
| Date | FY | Mod | Action type | Obligation | Company in company totals |
|---|---|---|---|---|---|
| Jul 29, 2022 | FY2022 | P00007 | B | $0.00 | — |
| Feb 25, 2022 | FY2022 | P00006 | B | $0.00 | — |
| Sep 14, 2021 | FY2021 | P00005 | A | $2,940,000,000.00 | — |
| Jul 26, 2021 | FY2021 | P00004 | D | $0.00 | — |
| Jul 8, 2021 | FY2021 | P00003 | M | $0.00 | — |
| Jun 17, 2021 | FY2021 | P00002 | B | $0.00 | — |
| Mar 9, 2021 | FY2021 | P00001 | M | $0.00 | — |
| Jan 12, 2021 | FY2021 | 0 | — | $2,625,000,000.00 | — |
Newest first. Every obligation is shown as reported, including zero and negative (de-obligation) actions. Award lists belong to the company of the latest action; company totals credit each action to the company named on that row, so a note marks rows where the two differ.